Tedizolid: the first once daily oxazolidinone class antibiotic.
Clin Infect Dis. 2015 Jun 23;
Authors: Burdette SD, Trotman R
Tedizolid phosphate is the second commercially available oxazolidinone antibiotic though the first one in class that is dosed once daily. It is a prodrug that is rapidly converted to the active compound tedizolid. Tedizolid has activity against a wide range of gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved to treat acute bacterial skin and skin structure infection (ABSSSI). In two randomized controlled phase 3 trials, 6 days of tedizolid (200mg once daily) has been proven to be non-inferior to 10 days of linezolid (600mg twice daily). These 2 ABSSSI studies have positioned tedizolid amongst the growing armamentarium of newer, novel, anti-gram positive agents. Tedizolid appears to differ from linezolid in the incidence of gastrointestinal and hematologic side effects and appears to lack drug interactions selective serotonin reuptake inhibitors (SSRI). Conditions other than ABSSSI are currently being evaluated in clinical studies.
PMID: 26105167 [PubMed - as supplied by publisher]